Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 1
1996 2
1997 3
1998 4
1999 3
2000 2
2001 1
2002 6
2003 4
2004 9
2005 9
2006 4
2007 3
2008 5
2009 2
2010 11
2011 9
2012 15
2013 7
2014 7
2015 6
2016 4
2017 3
2018 1
2019 3
2020 1
2021 1
2023 1
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivchev L, Niemann CU, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: strumberg d. Blood. 2024 Oct 31;144(18):1924-1935. doi: 10.1182/blood.2024024631. Blood. 2024. PMID: 39082668 Free PMC article. Clinical Trial.
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Mai EK, et al. J Clin Oncol. 2025 Apr 10;43(11):1279-1288. doi: 10.1200/JCO-24-02266. Epub 2024 Dec 9. J Clin Oncol. 2025. PMID: 39652594 Free PMC article. Clinical Trial.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Khorana AA, et al. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
Regorafenib for cancer.
Strumberg D, Schultheis B. Strumberg D, et al. Expert Opin Investig Drugs. 2012 Jun;21(6):879-89. doi: 10.1517/13543784.2012.684752. Expert Opin Investig Drugs. 2012. PMID: 22577890 Review.
Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial.
Gaedcke J, Sahrhage M, Ebeling M, Azizian A, Rühlmann F, Bernhardt M, Grade M, Bechstein WO, Germer CT, Grützmann R, Piso P, Hofheinz RD, Staib L, Beißbarth T, Kosmala R, Fokas E, Rödel C, Ghadimi M; German Rectal Cancer Study Group. Gaedcke J, et al. Sci Rep. 2025 Feb 13;15(1):5401. doi: 10.1038/s41598-024-83105-z. Sci Rep. 2025. PMID: 39948076 Free PMC article. Clinical Trial.
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Al-Sawaf O, Fürstenau M, Giza A, Robrecht S, von Tresckow J, Fink A, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer AP, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindstrom V, Staber PB, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann CU, Fischer K, Eichhorst BF, Hallek MJ. Al-Sawaf O, et al. Among authors: strumberg d. Blood. 2025 Aug 27:blood.2025028899. doi: 10.1182/blood.2025028899. Online ahead of print. Blood. 2025. PMID: 40864973 Free article.
The neuroepithelial origin of ovarian carcinomas explained through an epithelial-mesenchymal-ectodermal transition enhanced by cisplatin.
Díaz-Carballo D, Safoor A, Saka S, Noa-Bolaño A, D'Souza F, Klein J, Acikelli AH, Malak S, Rahner U, Turki AT, Höppner A, Kamitz A, Song W, Chen YG, Kamada L, Tannapfel A, Brinkmann S, Ochsenfarth C, Strumberg D. Díaz-Carballo D, et al. Among authors: strumberg d. Sci Rep. 2024 Nov 26;14(1):29286. doi: 10.1038/s41598-024-76984-9. Sci Rep. 2024. PMID: 39592661 Free PMC article.
Raf kinase inhibitors in oncology.
Strumberg D, Seeber S. Strumberg D, et al. Onkologie. 2005 Feb;28(2):101-7. doi: 10.1159/000083373. Onkologie. 2005. PMID: 15665559 Review.
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.
Dührsen U, Bockisch A, Hertenstein B, Karsten IE, Kroschinsky F, Heuser M, Hochhaus A, Höffkes HG, Behringer D, Prange-Krex G, Tometten M, Grieshammer M, Grigoleit GU, Schmalz O, Jordan K, Bernhard H, Gaska T, Giagounidis A, Schroers R, Martens UM, Held G, Klapper W, Jöckel KH, Nonnemacher M, Hüttmann A; PETAL Trial Investigators. Dührsen U, et al. Blood Neoplasia. 2024 May 21;1(3):100018. doi: 10.1016/j.bneo.2024.100018. eCollection 2024 Sep. Blood Neoplasia. 2024. PMID: 40453056 Free PMC article. Clinical Trial.
122 results